$ImmunityBio (IBRX.US)$ Excited to see the rapid momentum with the second USA-Saudi Biotech Alliance summit hosted by @InvestSaudi to continue our strategic dialogue and meet with oncology leaders covering multiple tumor types. "The Science behind Investment in Biotech: Clinical & Scientific Breakthroughs" hosted by @InvestSaudi and @NGHAnews. Extending breakthrough therapies in the Middle East. Details soon! 🇺🇸🇸🇦
Dr PSS

$ImmunityBio (IBRX.US)$ Independent of the overall market, this week it stabilized at 6. Next week, aim for 7.

$ImmunityBio (IBRX.US)$ Patrick Soon on video: "I was just on the phone last night with the head of the Saudi Arabia FDA who says we want to now expose this to all tumor types"🥳🥳🥳🥳🥳

$ImmunityBio (IBRX.US)$ The 2nd USA: Saudi Biotech Alliance summit to be held this month in Rhiyadh - this time a sharing of all the combinations of Anktiva and NK cell therapy with oncology thought leaders and leadership in Saudi and setting the launch of Anktiva with NKcell therapy- immunotherapy 2.0 . Really exciting to share our decades of work and expand the Bioshield indications. The clinical trial results validating NantCancer vaccine patent, now the Bioshield, will be shared across multip...

$ImmunityBio (IBRX.US)$ 1. Expected Approval for Bladder Cancer Sales in Europe and the UK by February
- Sales will expand across Europe immediately upon approval, serving as a direct catalyst for an explosive revenue surge in 2026.
2. Expansion of Indications and New Biologics License Application (BLA)
- Expectations for NSCLC (Non-Small Cell Lung Cancer) BLA submission and approval: The BLA submission to the U.S. FDA to expand the indication for lung cancer is scheduled to proceed.
3. Appro...

$ImmunityBio (IBRX.US)$ Dr. Patrick Soon-Shiong on Megyn Kelly:
“Elephants have 8 copies of the tumor-suppressor gene p53. Humans have only 1.
Our lab found COVID knocks down p53 exactly like HPV does before it triggers cancer 5–10 years later.
We’re now seeing head & neck cancers surge past cervical cancer numbers in the US. I’ve personally treated 6 patients with our new protocol… all 6 had dramatic responses.”

$ImmunityBio (IBRX.US)$ The risk of holding cash is much greater than the risk of holding positions, positive news can come at any time. Buy and hold.

$ImmunityBio (IBRX.US)$ $IBRX - 7000 short shares available touching 0 multiple times. Time to cover 5.98 days. I think we are in an extremely good position. The market's favorite stocks got hammered while $IBRX held up relatively good, trapping more shorts in the process. If we continue holding this relative strength, a recovery should annihilate shorts. That is just the technicals. We have so many upcoming catalysts from a regulatory, global expansion and pipeline point of view. I genuinely wou...

$ImmunityBio (IBRX.US)$ $IBRX demonstrated impressive relative strength during yesterday’s broader market sell-off, holding far better than many peers in biotech and beyond. This resilience highlights growing investor confidence in its explosive growth story (ANKTIVA ramp, pipeline catalysts) while positioning it as a smart hedge against bearish macro pressures—more buyers are likely stepping in on these dips.”

$ImmunityBio (IBRX.US)$ Dr. Patrick Soon-Shiong says protecting humans’ immune systems better than we do now could be worth tens of trillions of dollars.
“One year of increasing aging—in terms of longevity by protecting your immune system—is worth $38 trillion dollars.”
“10 years is $367 trillion.”
“That alone could change not only everything with regard to our healthcare system, but the entire debt structure of the country.”